Avalo Therapeutics Inc. Common Stock (AVTX)
Stock · NASDAQ · Health Care
$11.27as of 10/16/2026
Price chart
Active signals
AVTX Signal Track Record
How signals performed across all stocks →What AVTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | -3.2% | 44% | September 11, 2026 |
| Bollinger Band Breakout | 24 | -2.4% | 46% | August 19, 2026 |
| Bollinger Band Breakdown | 19 | -8.8% | 42% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +17.5% | 56% | June 17, 2026 |
| Any 20-session window (baseline) | -4.7% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About AVTX
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, In…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 33
- Website
- www.avalotx.com/
Fundamentals
- 1-day range
- $12.09$13.23
- Market cap
- $989.29M
- P/E (trailing)
- —
- P/E (forward)
- -4.49
- EPS (trailing)
- $-4.75
- Dividend yield
- —
- Beta
- 0.61
- Avg. volume
- 919.7K
How Avalo Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Avalo Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- AVTXAvalo Therapeutics Inc. Common Stock$11.27▼ 6.16%Market cap $989.29MP/E —$12.51$24.27
- OPKOPKO Health Inc. Common Stock$1.53▼ 4.97%Market cap $985.15MP/E —$0.98$1.75
- JANXJanux Therapeutics Inc. Common Stock$16.51▼ 4.68%Market cap $981.85MP/E —$12.12$35.34
- GERNGeron Corporation Common Stock$1.17▼ 4.88%Market cap $1.01BP/E —$1.04$2.01
- ANLAdlai Nortye Ltd. American Depositary Shares$11.03▼ 8.77%Market cap $1.01BP/E —$0.879$17.25
- PCRXPacira BioSciences Inc. Common Stock$36.34▲ 0.03%Market cap $1.02BP/E 98.88$18.8$36.46
- OMEROmeros Corporation Common Stock$16.2▼ 13.78%Market cap $951.74MP/E 10.87$4.06$21.24
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| AVTX Avalo Therapeutics Inc. Common Stock | $989.29M | — | $11.27 | ▼ 6.16% | $12.51$24.27 |
| OPK OPKO Health Inc. Common Stock | $985.15M | — | $1.53 | ▼ 4.97% | $0.98$1.75 |
| JANX Janux Therapeutics Inc. Common Stock | $981.85M | — | $16.51 | ▼ 4.68% | $12.12$35.34 |
| GERN Geron Corporation Common Stock | $1.01B | — | $1.17 | ▼ 4.88% | $1.04$2.01 |
| ANL Adlai Nortye Ltd. American Depositary Shares | $1.01B | — | $11.03 | ▼ 8.77% | $0.879$17.25 |
| PCRX Pacira BioSciences Inc. Common Stock | $1.02B | 98.88 | $36.34 | ▲ 0.03% | $18.8$36.46 |
| OMER Omeros Corporation Common Stock | $951.74M | 10.87 | $16.2 | ▼ 13.78% | $4.06$21.24 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Sullivan Christopher Ryan · September 16, 2026 · Option Exercise12.4K @ $9.88
- Sullivan Christopher Ryan · September 16, 2026 · Sale12.4K @ $16.33
- Sullivan Christopher Ryan · September 10, 2026 · Option Exercise10.2K @ $8.04
- Sullivan Christopher Ryan · September 10, 2026 · Sale10.2K @ $17.62
- Doyle Mittie · August 28, 2026 · Option Exercise679 @ $8.04
- Doyle Mittie · August 28, 2026 · Sale679 @ $20
- Sullivan Christopher Ryan · August 18, 2026 · Option Exercise31.0K @ $9.88
- Sullivan Christopher Ryan · August 18, 2026 · Sale31.0K @ $20.05
- Doyle Mittie · August 17, 2026 · Option Exercise1.0K @ $12.65
- Doyle Mittie · August 17, 2026 · Sale1.0K @ $20
- Sullivan Christopher Ryan · August 17, 2026 · Option Exercise2.9K @ $9.88
- Sullivan Christopher Ryan · August 17, 2026 · Option Exercise37.9K @ $9.88
- Sullivan Christopher Ryan · August 17, 2026 · Sale3.7K @ $19.94
- Sullivan Christopher Ryan · August 17, 2026 · Sale37.9K @ $19.85
- Riley Jennifer · August 11, 2026 · Sale2.7K @ $19.59
Institutional Ownership
March 31, 2026
- Total shares held
- 33.98M
- Total value held
- $474.34M
- Institutional holders
- 97
- Unknown2.88M
- Unknown2.16M
- Unknown1.64M
- Unknown1.63M
- Unknown1.41M
- Unknown1.34M
- Unknown1.30M
- Unknown1.24M
- Unknown1.14M
- Unknown1.09M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program
Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.
Avalo Therapeutics Reports Phase 2 Progress on IL-1β Program. Avalo Therapeutics disclosed Phase 2 validation for its IL-1β franchise, a development that could expand the company's pipeline in inflammatory disease treatments. The biotech firm also announced inducement stock grants to new hires under Nasdaq listing rules and scheduled participation in investor conferences, routine corporate activities that signal active business expansion. The stock trades within its 52-week range, with the analyst consensus target notably above current levels.